GLG Partners’s iShares Biotechnology ETF IBB Stock Holding History

GLG Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-225,000	Closed	-$21.7M	–	412
2016 Q3	$21.7M	Buy	+225,000	New	+$21.4M	0.67%	29

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GLG Partners's IBB Position: Q3 2016 in Review

GLG Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2016, closing a stake of 2,913 shares — an estimated $277K sold.

GLG Partners first reported a position in IBB in Q3 2014 and held it in 5 quarters. The position peaked at $7.21M in Q3 2014. 464 funds tracked by Wall St. Rank hold IBB as of Q3 2016.

GLG Partners reported no remaining iShares Biotechnology ETF position as of Q3 2016 after selling out during the quarter.
GLG Partners sold 2,913 iShares Biotechnology ETF shares in Q3 2016, an estimated $277K.
GLG Partners first reported a position in iShares Biotechnology ETF in Q3 2014 and held it in 5 quarters.
GLG Partners's iShares Biotechnology ETF position peaked at $7.21M in Q3 2014.
464 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2016.

Based on GLG Partners's 13F filing for Q3 2016, filed 14 Nov 2016.